Tobias Bexte

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Come together: The BE-TILs-Efficient multiplex base editing of tumor-infiltrating lymphocytes.

Come together: The BE-TILs-Efficient multiplex base editing of tumor-infiltrating lymphocytes.

Journal: Molecular therapy. Oncology
Published: February 20, 2026

Engineering with care: safety assessment platforms for CRISPR-modified natural killer cells.

Engineering with care: safety assessment platforms for CRISPR-modified natural killer cells.

Journal: Frontiers in immunology
Published: September 23, 2025

Next-generation multiplex-edited CAR-NK cells: more edits, more power?

Next-generation multiplex-edited CAR-NK cells: more edits, more power?

Journal: Journal for immunotherapy of cancer
Published: August 26, 2025

Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy.

Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy.

Journal: Journal for immunotherapy of cancer
Published: May 28, 2025

Migration Dynamics of Human NK Cell Preparations in Microchannels and Their Invasion Into Patient-Derived Tissue.

Migration Dynamics of Human NK Cell Preparations in Microchannels and Their Invasion Into Patient-Derived Tissue.

Journal: Journal of cellular and molecular medicine
Published: October 11, 2024

Empowering virus-free CAR immune cell therapies.

Empowering virus-free CAR immune cell therapies.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: May 04, 2024

Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.

Engineering of potent CAR NK cells using non-viral Sleeping Beauty transposition from minimalistic DNA vectors.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: January 23, 2024

The RHOA Mutation G17V Does Not Lead to Increased Migration of Human Malignant T Cells but Is Associated with Matrix Remodelling.

The RHOA Mutation G17V Does Not Lead to Increased Migration of Human Malignant T Cells but Is Associated with Matrix Remodelling.

Journal: Cancers
Published: May 26, 2023

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.

Journal: Nature communications
Published: January 17, 2023

Nonviral technologies can pave the way for CAR-NK cell therapy.

Nonviral technologies can pave the way for CAR-NK cell therapy.

Journal: Journal of leukocyte biology
Published: December 03, 2022

CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.

CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.

Journal: Oncoimmunology
Published: June 13, 2022

Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy.

Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy.

Journal: Cancers
Published: February 21, 2021
Showing 1-12 of 14

Last Updated: 09/26/2026